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Abstract: Cardiovascular disease is the leading cause of death in Western countries and current research is still focusing 
on optimizing therapeutic approaches in the battle against this multifactorial disease. Concepts regarding the pathogenesis 
of many cardiovascular diseases originate from observations of human atherosclerotic tissue obtained from autopsies or 
during vascular surgery. These observations have helped us to disentangle the pathophysiology of atherosclerosis. How-
ever, identifying vulnerable patients, those prone to developing cardiovascular complications, remains difficult. The 
search for predictive cardiovascular biomarkers continues and large, well organized biobanks are needed to discover or 
validate novel biomarkers. Biobanks are an extremely valuable resource that enables us to study the influence of both ge-
netic and environmental factors on the development of multifactorial diseases such as atherosclerosis. This review will fo-
cus on the advantages and pitfalls in atherosclerotic biobanking. 
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WHY BIOBANKING? 
  Biobanks are organized resources of biological samples 
with associated clinical characteristics used for scientific 
investigation, they can be population or disease based [1]. 
The storage of tissue varies considerably, ranging from well-
organized formal repositories to the informal storage of tis-
sue specimens in a researcher’s freezer. While in the past, 
tissue collection was performed by local pathology depart-
ments dealing with local operating procedures, biobanks 
have become much more sophisticated and now work with 
stringent standard operating procedures (SOP’s) for tissue 
collection, processing and storage. In the last decade, the 
number of biobanks has increased significantly. In the 
United States (US) alone, an estimated 1 billion dollars has 
been invested in biobanking [2] and it has been conserva-
tively estimated that more than 300 million tissue specimens 
are stored from more than 180 million cases [3]. But what 
are the advantages of biobanks?  
  Firstly, biobanks are an important resource for identify-
ing the causes and mechanisms of many complex diseases. 
Biobanks enable scientists to investigate the combined influ-
ence of genetics, life style and other environmental factors in 
the development of multifactorial diseases. In addition, 
biobanks create the possibility for scientists to collect human 
material prior to presentation of specific diseases and pro-
vide the ability to compare different disease stages at a mo-
lecular level. Identification of pathways involved in disease 
initiation or progression may lead to the discovery of new 
therapeutic targets but also may result in the detection of 
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biomarkers for prediction of disease progression or outcome. 
Furthermore, biobanks also play an important role in the 
process of validation of novel discovered biomarkers. 
  Secondly, biobanks are highly relevant for scientists in 
case of rare disorders. In order to investigate rare disorders, 
researchers would have to wait for years to collect enough 
material to be able to reject or confirm their hypothesis. 
Therefore, a biobank consisting of human material of pa-
tients with rare disorders is valuable and will save years.
  Finally, disease based biobanks are needed to validate 
discoveries made in animal models. Regarding cardiovascu-
lar disease, animal studies have helped us greatly to elucidate 
the pathophysiology of atherosclerosis. One of the most 
studied animals in atherosclerotic research is the Apo E 
knockout mouse and major steps in the understanding of 
cardiovascular disease have been made by these animal stud-
ies. But although these mice do develop progressive athero-
sclerotic lesions, plaque rupture and its consequent cardio-
vascular complications do not occur. Therefore, to obtain 
further knowledge in the process of plaque rupture and the 
occurrence of cardiovascular complications novel ways to 
investigate this multifactorial disease are needed and human 
atherosclerotic biobanks can play major roles in this process. 
ATHEROSCLEROTIC TISSUE BIOBANKS: A HIS-
TORICAL REVIEW 
  Atherosclerotic tissue biobanks have led to the descrip-
tion of etiologic concepts that dominated basic research fo-
cused on disentangling the pathogenesis of atherosclerosis. 
Major steps in this process were taken by observations of 
large amounts of atherosclerotic specimens obtained from 
autopsy. In the late 18
th century, Rudolph Virchow examined 
atherosclerotic arteries obtained from autopsies and noticed 
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wall and introduced the term endarteritis deformans [4]. It 
was one of the first in-depth studies to focus on histological 
characteristics of the atherosclerotic lesion. One century 
later, Russell Ross combined histological observations in 
atherosclerotic specimens with in vivo experiments [5] and 
postulated his famous response to injury theory [6]. Michael 
Davies was one of the pioneers of thrombus formation, he 
defined three stages of thrombus evolution due to plaque 
rupture: intraplaque thrombus, transitional or mural throm-
bus, and occlusive thrombus [7]. He also provided an excel-
lent overview of previous histological studies that demon-
strated plaque vulnerability to be a function of increased 
numbers of macrophages, reduced smooth muscles and a 
large lipid core with a thin fibrous cap [8-11]. Dr. Virmani’s 
group investigated acute coronary artery thrombosis in pa-
tients with sudden cardiac death and found out that the ma-
jority was caused by plaque rupture (60%), but also plaque 
erosion (35%) and finally calcified noduli contributed to 
arterial thrombosis (5%) [12]. These studies are all examples 
of how observations of large tissue cohorts have helped un-
ravel the pathophysiology of atherosclerosis. Hurks and col-
leagues published a detailed overview of the history of athe-
rosclerotic biobanking [13].  
THE VULNERABLE PLAQUE 
  The vulnerable plaque, prone to rupture, is characterized 
by its large lipid core covered by a thin fibrous cap, large 
macrophage infiltration and low smooth muscle cell content. 
The aforementioned studies all contributed to the vulnerable 
atherosclerotic plaque paradigm. Overviews and histological 
classifications of the vulnerable plaque have been published 
over the years [14-16] and multiple definitions have been 
documented. Detection of these lesions before rupture is 
difficult although progress has been made. A recent review 
summarized several newly developed imaging modalities to 
detect the so called thin cap fibro-atheroma (TCFA), the pre-
cursor of ruptured plaques [14]. However, all of these imag-
ing modalities have the major limitation that only a certain 
part of the vascular tree can be visualized. Since atheroscle-
rosis is a systemic disorder one can only speculate where to 
look for the so called vulnerable plaques.  
  The vulnerable plaque concept carries an important limi-
tation which is an inherent drawback of most tissue biobank 
studies—it is based on cross-sectional and retrospective 
studies on ruptured plaques. Robust prospective, longitudinal 
studies on vulnerable plaque characteristics and outcome are 
lacking. In addition, hallmarks of the vulnerable plaque, in-
flammation and a large lipid core, can also be observed in 
asymptomatic patients and can be considered as a common 
and locally observed phenomena of the whole vascular tree 
[17]. Also, it is important to realize that not all ruptured 
plaques will cause arterial thrombosis. Silent rupture with 
plaque progression occurs [18] and 20% of asymptomatic 
carotid arteries show signs of plaque rupture at postmortem 
examination [19]. It is therefore questionable if detection of 
precursor lesions of the vulnerable plaque will result in iden-
tification of those patients that will develop a plaque rupture. 
Because of these limitations, novel strategies are being de-
veloped to detect patients at increased risk for plaque rup-
ture. Naghavi et al introduced the term ‘vulnerable patient’ 
in 2003 [20]. They reported that the clinical presentation of a 
plaque rupture is influenced not only by plaque vulnerability, 
but also by thrombogenic blood (vulnerable blood), and elec-
trical instability of the myocardium (vulnerable heart). The 
quest for identification of this vulnerable patient resulted in 
many large scale population studies, trying to find the holy 
grail that is being able to detect those patients at increased 
risk for cardiovascular events. Thus, although the concept of 
the vulnerable plaque resulted in important insights in patho-
genesis of the disease, it may not optimally serve as a basis 
for prediction of the patient at risk of suffering a cardiovas-
cular event.  
POPULATION BASED BIOBANKS AND THE 
SEARCH FOR PREDICTIVE BIOMARKERS IN CVD 
  One of the first and famous examples of a population 
based biobank was the Framingham Heart Study. In 1951, 
28,000 citizens from the town Framingham (US) were en-
rolled and periodically monitored. The occurrence of cardio-
vascular events was correlated with data from physical ex-
aminations, questionnaires and laboratory tests [21]. The 
Framingham Heart Study gave rise to many novel insights in 
the pathophysiology of cardiovascular disease and ultimately 
resulted in the Framingham Heart risk score for risk stratifi-
cation of cardiovascular disease. It is an excellent example of 
a large scale study that is able to reveal factors that influence 
multifactorial diseases.  
  In order to identify the vulnerable patient, several large 
scale population based biobanks have attempted to find 
novel serum biomarkers to predict cardiovascular risk more 
accurately than traditional risk factors. Several biomarkers 
have been found to be strongly associated with future car-
diovascular events but on top of the traditional risk factors 
their extra predictive value was limited [22-26]. Even the 
addition of multi-marker panels on top of traditional risk 
factors has so far resulted in no or small increases in the dis-
criminative power to detect patients at risk [27-29]. Zethelius 
showed improved discriminative power (the so called C-
statistics,) when 4 markers (troponin I, N-terminal pro-brain 
natriuretic peptide, cystatin C and C-reactive protein) were 
added to the traditional risk factor model in 1135 elderly 
men [30]. However, more work is needed before multi-
marker panels can provide a basis for prognostic evaluation 
of the individual patient [31].  
OPPORTUNITIES IN BIOBANKING 
  Cross-sectional atherosclerotic biobanks may help us to 
generate hypotheses regarding the mechanisms of athero-
genesis and its progression. However, for prediction (longi-
tudinal) studies follow up is required, therefore, atheroscle-
rotic biobanks with a longitudinal study design might facili-
tate the discovery of biomarkers that are predictive for future 
cardiovascular events. Taking into account that atherosclero-
sis has been considered as a systemic disease [32] and that 
plaque composition corresponds between different arterial 
segments [33], one could speculate that local plaque charac-
teristics represent plaque progression in other territories of 
the vascular tree. Therefore, atherosclerotic plaques, ob-
tained during vascular surgery, might contain markers pre-
dictive for future cardiovascular events. One example of this 
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prospective cohort study started in 2002 [34]. The Athero-
express study, of more than 1500 patients, correlates charac-
teristics of dissected plaques with secondary cardiovascular 
manifestations acquired during a three year follow-up. 
Hellings  et al showed that plaque composition is an inde-
pendent predictor of restenosis after carotid endarterectomy. 
They demonstrated that patients with more stable plaque 
phenomena had an increased risk for the development of 
restenosis compared with patients with unstable plaque phe-
nomena [35]. This was the first example that atherosclerotic 
plaques contain predictive information about outcome fol-
lowing surgery. Recently de Kleijn et al demonstrated that 
local plaque proteins are a source of biomarkers with strong 
predictive value for future cardiovascular events [36]. 
Analysis of the proteome of atherosclerotic plaques, from 
patients with and without secondary cardiovascular manifes-
tations, revealed osteopontin (OPN) as a potential predictive 
marker. Validation of this marker in a large cohort demon-
strated that patients within the highest quartile of plaque 
OPN levels had a 4 fold increased risk for secondary cardio-
vascular events compared with patients in the lowest quartile 
of OPN [36]. Thus, the OPN levels in one small dissected 
plaque revealed information regarding the risk of secondary 
manifestations during 3 years follow up. Unfortunately, 
these predictive markers are measured in surgically obtained 
specimens and these snapshots are not able to monitor the 
effect of treatment or intervention, therefore the clinical util-
ity of predictive plaque markers is limited.  
  While established circulating biomarkers are, on top of 
established risk factors, limited in the prediction of future 
cardiovascular events, the search for identification of the 
vulnerable patient continues. One example of a novel strat-
egy is the Circulating Cells project. The Centre of Transla-
tional Molecular Medicine (CTMM), a consortium of 5 
Dutch academic centers collaborating with industrial part-
ners, started this multicenter study in 2009 [37]. In this 
study, blood will be obtained from at least 500 patients prior 
to percutaneous coronary intervention (PCI). Activation 
markers and responsiveness of the circulating cells will be 
measured and correlated with future cardiovascular events. 
Different cell fractions will be stored and used for detection 
of novel biomarkers by using a proteomic approach to com-
pare the proteome of patients with and without a cardiovas-
cular event. Hopefully novel predictive biomarkers will be 
found and, after validation, used in a clinical setting to detect 
those patients at increased risk.  
  Another opportunity is the rapidly growing field of ge-
nomics. Sequencing of the human genome continues and 
large population based biobanks enable scientists to investi-
gate the effect of the genomic variability on cardiovascular 
disease. A lot of attention has been received by the Genome 
Wide Association (GWA) studies in which allelic frequency 
variations in single nucleotide polymorphisms (SNP’s) are 
compared between patients with or without cardiovascular 
manifestations [38]. These GWA studies had a major boost 
in 2007 when 4 independent large scaled studies reported 
that the same SNP, located on chromosome 9p21.3, was as-
sociated with coronary heart disease and myocardial infarc-
tion and confirmed an increased risk predisposition [39-42]. 
Knowledge of the genetic predisposition for cardiovascular 
disease may improve clinical management and translation 
might be effected by two principal routes. Firstly, the dis-
covery of regions of the genome that are associated with 
disease will reveal novel causal pathways and identify poten-
tial new therapeutic targets. Secondly, the knowledge of in-
dividual patterns of disease predisposition can be used to 
develop a more personalized disease management. In the 
future, novel susceptibility loci will be discovered and this 
information will shed light on the complex relationships be-
tween changes in the genome and disease phenotype.  
  With the increasing understanding in the pathogenesis of 
atherosclerosis, substantial progression has been made in the 
development of novel imaging techniques to detect the so 
called vulnerable plaque. Due to a lack of a golden standard, 
atherosclerotic biobanks play important roles in the valida-
tion process of these novel imaging technologies. Magnetic 
resonance imaging (MRI) has emerged as a promising novel 
technique with its superior capability to determine plaque 
size and composition (regarding lipid-rich necrotic core and 
intraplaque haemorrhage) and with a high intra-reader, inter-
reader and inter-scan reproducibility [43]. High resolution 
MRI scans have also been combined with novel tracer tech-
niques. One example is the use of ultra-small super par-
amagnetic particles of iron oxide that are able to accumulate 
passively in plaque macrophages and therefore can be used 
to visualize plaque macrophages [44]. Molecular MRI is 
another promising field where antibodies against oxidized-
LDL, Vascular Cel Adhesion Molecule-1 (VCAM-1) and 
Matrix Metallo Proteases (MMP’s) are linked with ra-
diotracers and can be used to visualize different atheroscle-
rotic molecular markers. In the near future, clinical imple-
mentation of plaque imaging techniques is likely to occur 
and will enable physicians not only to detect vulnerable pa-
tients but also monitor the effect of different treatment mo-
dalities.  
CHALLENGES AND PITFALLS 
  With the increasing number of biobanks and increasing 
opportunities to store different cell fractions some challenges 
and pitfalls merit careful consideration. While Rudolph 
Virchow drew conclusions from autopsy specimens obtained 
from a limited number of patients, research now may include 
thousands of patients. Enormous databases are needed to 
store the data obtained from long questionnaires, cytokine 
profiles, genomics and proteomics. Thus, presenting re-
searchers with a challenge to work effectively and efficiently 
with such datasets. Fortunately, novel software and analyti-
cal programs are available. Large online databases like on-
line mendelian inheritance in man (OMIM
®) and ingenuity 
pathway analysis (IPA
®) provide useful tools to find novel 
pathways and collaborate with other scientists.  
  There is a need for the simultaneous assessment of multi-
ple markers. Availability of tissue and blood may be limited, 
especially of patients who are defined as a “case”. Therefore 
techniques have been developed that enable quantitative as-
sessment of many markers simultaneously and require lim-
ited sample volumes. An example of a now frequently used 
tool, is the multiplex immunoassay technology (MIA). Cyto-
kines reflect local or systemic inflammation and might there-
fore be a suitable target in the continuing quest for novel 
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can only detect one cytokine in one sample, MIA enables 
detection of multiple cytokines, chemokines and other pro-
teins in one single sample and therefore prevents spoiling 
large amounts of valuable and often limited human blood.  
  Recent studies raised a serious concern regarding storage 
of samples in biobanking. Large population biobanks, but 
also large conducted randomized clinical trials frequently 
measure proteins at different points in time using frozen 
samples. However, sampling, handling and storage can 
greatly influence the reproducibility and reliability of these 
immunoassays. De Jager et al demonstrated that the type of 
anticoagulant used can influence the levels of several cytoki-
nes [45]. In addition, they demonstrated that most cytokines 
are stable for up to two years of storage but degrade after 
that, with most cytokines reaching almost 25% of its original 
value after two years [45]. They emphasized the importance 
of internal controls and quality checks. 
  Biobanks and their relevant medical ethics committees 
carry a serious responsibility to the patients from whom they 
collect their samples. Legislation of privacy issues in cardio-
vascular biobanking is well organized for some issues such 
as that patients’ data must be anonymously processed. But it 
is also important to ask patients, before admission to the 
study, what to do in case of discovery of novel beneficial or 
adverse biomarkers. Patients should be well informed about 
the possibilities in case of such discoveries. Secondly, it is 
important to define who owns the tissue in case of long term 
storage. As the number of biobanks increases so does the 
number of private companies offering to store cells. One of 
the first examples of commercialised biobanking interfering 
with concerns about ownership and privacy issues was the 
Iceland Biogenetic Project. In this project the involvement of 
deCODE genetics, a commercial company with monopoly 
rights over scientific discoveries generated within the pro-
ject, generated concerns about the commercialisation of the 
material and sensitive personal information that was being 
collected without the explicit informed consent of individu-
als [46]. These concerns were broadly discussed in the media 
and finally resulted in new legislation. From now on all citi-
zens in Iceland are included in this bank unless they file a 
special opt-out request form. Another example of the need 
Opportunities in Biobanking 
Atherosclerotic tissue banks with a longitudinal study design:  
Local plaque proteins are a source for biomarkers with strong predictive value for future cardiovascular events. 
The quest for novel biomarkers:  
Correlate cardiovascular outcome with the expression of activation markers and responsiveness of the circulating cells from patients with coronary artery 
atherosclerosis. 
Genome Wide Association (GWA) studies 
Variations in single nucleotide polymorphisms (SNP’s) are compared between patients with or without cardiovascular manifestations and will reveal novel 
causal pathways and identify potential new therapeutic targets. 
Novel imaging techniques 
Progression has been made in detecting the so called vulnerable plaque. 
Some techniques already are at the precipice of translation to clinical practice. 
Challenges and pitfalls in Biobanking 
Deal with enormous datasets:  
Large online databases like OMIM
® and Ingenuity
®pathway analysis provide useful tools to find novel pathways. 
Attention towards trivial processes:  
Sampling, handling and storage can greatly influence the reproducibility and reliability of immunoassays.  
Legislation concerning privacy issues and ownership:  
Unified worldwide legislation regarding privacy issues and ownership is needed. 
Registration of biobanks 
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for well-defined privacy legislation was provided by a case 
in Sweden when the government bypassed informed consent 
rules to gain access to an anonymous sample, stored in a 
Swedish biobank, of a 25 year old, whose DNA matched 
with DNA found on the knife that was used to kill Swedish 
foreign minister Anna Lindh. Examples such as these may 
fuel the growing criticism of the privacy policies of 
biobanks. The European Union legislation concerning own-
ership is difficult and differs per country. In addition there 
are huge differences between European countries in terms of 
government involvement in biobanks. In some Scandinavian 
countries governments play major roles in the development 
of national biobanks [47], while in other countries govern-
ment involvement is very limited. With increasing interna-
tional collaboration efforts should be made to standardise 
legislation.  
  The third issue concerns registration. While it is obliga-
tory for randomized clinical trials to register before starting, 
registration for biobanks is not mandatory. In 1999, the Na-
tional Bioethics Advisory Commission of the US started an 
inventory about the amount of stored tissue in the United 
States, which resulted in the handbook of human tissue 
sources [3]. This was the first inventory of stored tissue in 
the US. In Europe a project was recently started by the Euro-
pean union, that enables biobanks to register in order to 
share data [1] which will hopefully facilitate future collabo-
ration.  
  In conclusion, biobanking of human tissue and blood 
samples is a hot topic. Biobanks enable us to investigate the 
complex interplay between genetics, environmental factors 
and the pathophysiological features of multifactorial dis-
eases. Important steps in the understanding of the patho-
physiology of atherosclerosis have been made by observa-
tions from large cohorts of atherosclerotic specimens. Al-
though the vulnerable plaque paradigm has some limitations, 
efforts have been made to develop novel imaging modalities 
to identify pre-cursor lesions and identify the vulnerable pa-
tient. On the other hand, the identification of the vulnerable 
patient continues with the assessment of multiple systemic 
biomarkers in the circulation in large scaled population stud-
ies. Until now, this identification process has not resulted in 
the golden bullet to identify the vulnerable patient. New op-
portunities in this field lie in the discovery of novel, more 
predictive biomarkers, in atherosclerotic tissue, but also in 
the more easy accessible circulation. Genome sequencing 
and genome-wide association studies will reveal more about 
the influence of genetics on atherosclerosis and hopefully 
will discover novel therapeutic targets. A lot of progress has 
been made in the development of novel imaging techniques 
to visualize unstable plaques and even some techniques are 
close to translation to the clinical practice. Pitfalls include 
trivial processes like handling and storage of patient mate-
rial. Challenges lie in collaboration of biobanks and world-
wide legislation and more important, registration of 
biobanks. 
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